The long-term cardiac impact of COVID-19

Study shows that severe COVID-19 elevates the long-term risk of major adverse cardiac events (MACE), making it comparable to coronary artery disease. It also highlights a genetic interaction with ABO blood type, influencing cardiovascular outcomes.

Canopy Growth Dilutes Its Stock After Big Rally

Canopy Growth Announces Financing to Further Strengthen Balance Sheet Including Approximately US$50 Million of New Gross Proceeds C$27.5 Millon of Debt Extended from 2025 to

May 3, 2024

FDA Could Soon Limit Use of Only Drug for COVID Prevention

Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced

August 28, 2024

Innovative tissue slicing method for improved clinical outcomes

In a pioneering development for the biomedical field, a research team led by Yuanjin Zhao from Nanjing Drum Tower Hospital, China, has published a research

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.